Insilico Medicine has announced a strategic partnership with Takeda to utilize its Pharma.AI platform for the development of novel drug candidates across various therapeutic areas. The collaboration aims to enhance the quality and efficacy of drug candidates using advanced generative AI models. Insilico will lead the AI-driven discovery process, while Takeda will leverage its global development capabilities for clinical validation. The agreement includes initial fees of approximately $60 million and potential total earnings of up to $600 million, granting Takeda exclusive rights to develop and commercialize resulting therapeutics.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://insilico.com/news/4ifuiaal01-insilico-medicine-announces-collaboratio
